Curis (NASDAQ:CRIS) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a research note issued on Thursday, February 8th.
According to Zacks, “Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis’ product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease. “
Separately, Guggenheim began coverage on shares of Curis in a research note on Monday, October 23rd. They set a “buy” rating and a $7.00 price objective on the stock. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $6.50.
Shares of Curis (NASDAQ:CRIS) opened at $0.54 on Thursday. Curis has a one year low of $0.48 and a one year high of $3.22. The company has a current ratio of 5.15, a quick ratio of 5.15 and a debt-to-equity ratio of 1.24.
Large investors have recently made changes to their positions in the company. FNY Partners Fund LP lifted its position in shares of Curis by 350.0% during the 3rd quarter. FNY Partners Fund LP now owns 67,500 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 52,500 shares in the last quarter. Thrivent Financial For Lutherans purchased a new position in shares of Curis during the 4th quarter valued at approximately $108,000. OxFORD Asset Management LLP purchased a new position in shares of Curis during the 2nd quarter valued at approximately $115,000. Voya Investment Management LLC lifted its position in shares of Curis by 21.8% during the 2nd quarter. Voya Investment Management LLC now owns 68,138 shares of the biotechnology company’s stock valued at $129,000 after buying an additional 12,207 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its position in shares of Curis by 338.7% during the 2nd quarter. Alliancebernstein L.P. now owns 83,800 shares of the biotechnology company’s stock valued at $158,000 after buying an additional 64,700 shares in the last quarter. Hedge funds and other institutional investors own 56.09% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/15/curis-cris-raised-to-hold-at-zacks-investment-research.html.
Curis Company Profile
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
Get a free copy of the Zacks research report on Curis (CRIS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.